POWAY, CA--(Marketwire - February 17, 2012) - Digirad Corporation (NASDAQ: DRAD) today reported 2011 fourth quarter revenue of $11.9 million, 2011 full-year revenue of $53.7 million and an ending cash and available-for-sale securities balance of $30.5 million at December 31, 2011.
Digirad CEO Todd Clyde commented, "We laid out four key goals at the beginning of the year: generate positive cash flow, increase ergo sales, expand margins in both our Product and DIS business units and return to year-over-year growth in the second half of the year. We achieved the first three goals, but fell short on revenue growth due to a relatively weak fourth quarter in the Product division.
Clyde continued: "Going forward, we are seeing improvements in the capital equipment environment, more activity in the sales funnel on the Product side, continued stabilization in reimbursements and new opportunities in new camera markets. In 2012, we expect to continue to generate positive cash flow from our DIS business and to increase sales of both our cardiac and ergo cameras. We invested in strategic market research in the fourth quarter -- resulting in a better understanding of where our core technologies can be applied with greater success. Management and the Board are in the final stages of determining the best strategic path toward returning to a growth platform, and we look forward to communicating the specifics of those plans in the near future."
Fourth Quarter 2011 Summary
- Total revenue for the fourth quarter of 2011 was $11.9 million, compared to $14.7 million for the same period in the prior year and $13.4 million in the third quarter of 2011. DIS-only revenue for the fourth quarter of 2011 was $9.0 million, compared to $9.4 million for the same period of the prior year and $9.3 million in the prior quarter. Product revenue for the fourth quarter of 2011 was $2.9 million, compared to $5.2 million for the same period of the prior year and $4.1 million in the prior quarter.
- Gross profit for the fourth quarter of 2011 was $3.1 million, or 26.0 percent of revenue, compared to $3.6 million, or 24.6 percent of revenue, in the same period of the prior year and $4.2 million, or 30.9 percent of revenue, in the prior quarter.
- Net loss for the fourth quarter of 2011 was $2.8 million, or $0.15 loss per share, compared to net loss of $0.6 million, or $0.03 loss per share, in the same period of the prior year and a net income of $0.1 million, or $0.01 per share, in the prior quarter.
- Cash and cash equivalents and available-for-sale securities totaled $30.5 million, or $1.61 per share as of December 31, 2011. Cash and cash equivalents and available-for-sale securities totaled $30.2 million, or $1.63 per share as of December 31, 2010.
- During the fourth quarter of 2011, DIS asset utilization was 56 percent on 130 systems (nuclear and ultrasound), compared to 58 percent on 132 systems (nuclear and ultrasound) in the prior year fourth quarter and 56 percent on 130 systems (nuclear and ultrasound) in the prior quarter.
2011 Full-Year Financial Highlights:
- Total revenue for 2011 was $53.7 million, compared to $56.2 million for the prior year. DIS revenue for 2011 was $37.8 million, compared to $39.5 million for the prior year, and Product revenue for 2011 was $16.0 million compared to $16.6 million for the prior year.
- Gross profit for 2011 was $14.8 million, or 27.5 percent of revenue, compared to $12.0 million, or 21.4 percent of revenue for the prior year.
- Net loss for 2011 was $3.3 million, or $0.18 loss per share, compared to net loss of $6.2 million, or $0.33 loss per share, for the prior year.
- During 2011, DIS asset utilization was 56 percent on 131 systems (nuclear and ultrasound), compared to 61 percent on 133 systems (nuclear and ultrasound) for the prior year.
Conference Call Information
A conference call is scheduled for 11:00 a.m. EST today to discuss the results and management's outlook. The call may be accessed by dialing 877-941-1427 five minutes prior to the scheduled start time and referencing Digirad. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at www.digirad.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.
About Digirad Corporation
Digirad is a leading provider of diagnostic imaging products, and personnel and equipment leasing services. For more information, please visit www.digirad.com. Digirad® and Cardius® are registered trademarks of Digirad Corporation.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding our ability to deliver value to customers, our expanded product and service offerings, including, the addition of the first large-field-of-view, solid state portable camera to the hospital marketplace, and our ability to generate positive cash flow in 2011. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with changes in business conditions, technology, customers' business conditions, reimbursement, radiopharmaceutical shortages, economic outlook, operational policy or structure, acceptance and use of Digirad's camera systems and services, reliability, recalls, and other risks detailed in Digirad's filings with the U.S. Securities and Exchange Commission, including Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.
Digirad Corporation
Consolidated Statements of Operations
(in thousands, except per share data)
Three Months Ended Year Ended
December 31, December 31,
---------------------- ----------------------
2011 2010 2011 2010
---------- ---------- ---------- ----------
Revenues:
DIS $ 8,956 $ 9,421 $ 37,794 $ 39,542
Product 2,926 5,236 15,951 16,641
---------- ---------- ---------- ----------
Total revenues 11,882 14,657 53,745 56,183
Cost of revenues:
DIS 7,090 7,649 29,672 32,561
Product 1,698 3,400 9,315 11,618
---------- ---------- ---------- ----------
Total cost of revenues 8,788 11,049 38,987 44,179
---------- ---------- ---------- ----------
Gross profit 3,094 3,608 14,758 12,004
Operating expenses:
Research and development 613 597 2,738 2,875
Marketing and sales 3,007 1,353 7,622 5,922
General and administrative 2,024 2,190 7,741 9,007
Amortization of intangible
assets 77 102 331 435
Restructuring loss (gain) -- -- (164) 355
---------- ---------- ---------- ----------
Total operating expenses 5,721 4,242 18,268 18,594
---------- ---------- ---------- ----------
Loss from operations (2,627) (634) (3,510) (6,590)
Other income (expense):
Interest income (expense) (199) 89 165 378
Other income (expense) -- (14) 3 (2)
---------- ---------- ---------- ----------
Total other income (199) 75 168 376
---------- ---------- ---------- ----------
Net loss $ (2,826) $ (559) $ (3,342) $ (6,214)
========== ========== ========== ==========
Net loss per common share
-basic and diluted $ (0.15) $ (0.03) $ (0.18) $ (0.33)
========== ========== ========== ==========
Weighted average shares
outstanding - basic 19,193 18,876 19,052 18,774
Weighted average shares
outstanding - diluted 19,193 18,876 19,052 18,774
========== ========== ========== ==========
Stock-based compensation
expense is included in the
above as follows:
Cost of DIS revenue $ 2 $ 4 $ 13 $ 26
Cost of Product revenue 23 20 99 60
Research and development 20 21 84 61
Marketing and sales 24 36 110 113
General and administrative 119 105 494 614
---------- ---------- ---------- ----------
Total stock-based
compensation expense $ 188 $ 186 $ 800 $ 874
---------- ---------- ---------- ----------
Digirad Corporation
Consolidated Balance Sheets
(In thousands, except share amounts)
December 31, December 31,
2011 2010
------------ ------------
Assets
Current assets:
Cash and cash equivalents $ 24,039 $ 20,459
Securities available-for-sale 6,413 9,788
Accounts receivable, net 6,320 7,527
Inventories, net 6,178 5,432
Other current assets 855 861
Restricted cash 194 --
------------ ------------
Total current assets 43,999 44,067
Property and equipment, net 5,367 7,185
Intangible assets, net 477 808
Goodwill 184 184
------------ ------------
Total assets $ 50,027 $ 52,244
============ ============
Liabilities and stockholders' equity
Accounts payable $ 1,330 $ 1,694
Accrued compensation 2,291 1,600
Accrued warranty 297 378
Deferred revenue 2,099 2,379
Other accrued liabilities 2,397 2,096
------------ ------------
Total current liabilities 8,414 8,147
Deferred rent 126 138
------------ ------------
Total liabilities 8,540 8,285
------------ ------------
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value: 10,000,000
shares authorized; no shares issued or
outstanding -- --
Common stock, $0.0001 par value: 80,000,000
shares authorized; 18,901,160 and 18,597,311
shares issued and outstanding (net of treasury
shares) at December 31, 2011 and 2010,
respectively 2 2
Treasury stock, at cost; 582,825 shares and
573,218 shares at December 31, 2011 and 2010,
respectively (1,058) (1,039)
Additional paid-in capital 155,704 154,785
Accumulated other comprehensive income 33 63
Accumulated deficit (113,194) (109,852)
------------ ------------
Total stockholders' equity 41,487 43,959
------------ ------------
Total liabilities and stockholders' equity $ 50,027 $ 52,244
============ ============
Investor Contact:
Matt Clawson
Allen & Caron
949-474-4300
Email Contact
Company Contact:
Richard Slansky
CFO
858-726-1600
Email Contact
